Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1.
The Fc (fragment crystallizable) is a common structural region in immunoglobulin gamma (IgG) proteins, IgG-based multi-specific platforms, and Fc-fusion platform technologies. Changes in conformational stability, protein-protein interactions, and aggregation of NS0-produced human Fc1 were quantified experimentally as a function of pH (4 to 6) and temperature (30 to 77 °C), using a combination of differential scanning calorimetry, laser light scattering, size-exclusion chromatography, and capillary electrophoresis. The Fc1 was O-glycosylated at position 3 (threonine), and confirmed to correspond to the intact IgG1 by comparison with Fc1 produced by cleavage of the parent IgG1. Changing the pH caused large effects for thermal unfolding transitions, but it caused surprisingly smaller effects for electrostatic protein-protein interactions. The aggregation behavior was qualitatively similar across different solution conditions, with soluble dimers and larger oligomers formed in most cases. Aggregation rates spanned approximately 5 orders of magnitude and could be divided into 2 regimes: (i) Arrhenius, unfolding-limited aggregation at temperatures near or above the midpoint-unfolding temperature of the CH2 domain; (ii) a non-Arrhenius regime at lower temperatures, presumably as a result of the temperature dependence of the unfolding enthalpy for the CH2 domain. The non-Arrhenius regime was most pronounced for lower temperatures. Together with the weak protein-protein repulsions, these highlight challenges that are expected for maintaining long-term stability of biotechnology products that are based on human Fc constructs.
a Department of Chemistry and Biochemistry ; University of Delaware ; Newark , DE USA.|b Department of Biotherapeutics ; Boehringer Ingelheim Pharmaceuticals Inc. ; Ridgefield , CT USA.
Haixia
H
Wu
b Department of Biotherapeutics ; Boehringer Ingelheim Pharmaceuticals Inc. ; Ridgefield , CT USA.
Kristopher
K
Truncali
b Department of Biotherapeutics ; Boehringer Ingelheim Pharmaceuticals Inc. ; Ridgefield , CT USA.
Julie
J
Ritchie
b Department of Biotherapeutics ; Boehringer Ingelheim Pharmaceuticals Inc. ; Ridgefield , CT USA.
Rachel
R
Kroe-Barrett
b Department of Biotherapeutics ; Boehringer Ingelheim Pharmaceuticals Inc. ; Ridgefield , CT USA.
Sanjaya
S
Singh
c Department of Chemical and Biomolecular Engineering ; Tulane University ; New Orleans , LA USA.|d Department of Chemical and Biomolecular Engineering ; University of Delaware ; Newark , DE USA.
Anne S
AS
Robinson
d Department of Chemical and Biomolecular Engineering ; University of Delaware ; Newark , DE USA.
Christopher J
CJ
Roberts
D002152:Calorimetry, Differential Scanning; D002850:Chromatography, Gel; D019075:Electrophoresis, Capillary; D006031:Glycosylation; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007141:Immunoglobulin Fc Fragments / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D007074:Immunoglobulin G / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D008958:Models, Molecular; D011485:Protein Binding; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D058767:Protein Unfolding; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D012996:Solutions / Q000737:chemistry; D055672:Static Electricity; D013696:Temperature; D013816:Thermodynamics; D013912:Threonine / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism
D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; D011993:Recombinant Fusion Proteins; D012996:Solutions; D013912:Threonine
antibody; kinetics; protein aggregation; protein formulation; protein stability